PRACTICE MANAGEMENT

Ascentage Pharma Presents Updates on its Global Clinical Development at the J.P. Morgan 39th Annual Healthcare Conference

Ascentage Pharma | January 14, 2021

Ascentage Pharma Presents Updates on its Global Clinical Development at the J.P. Morgan 39th Annual Healthcare Conference
Ascentage Pharma, an around the world engaged, clinical-stage biotechnology organization occupied with creating novel treatments for malignant growths, persistent hepatitis B (CHB), and age-related illnesses, introduced at the J.P. Morgan 39th Annual Healthcare Conference (a virtual occasion) at night of January 13, Beijing Time. During the introduction, Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, furnished business refreshes with an attention on the organization's worldwide R&D outline.

Dr. Yang conveyed a generally welcomed introduction on the organization's item pipeline and clinical advancement progress. As a worldwide pioneer in the improvement of therapeutics focusing on the protein-to-protein collaborations, Ascentage Pharma has assembled a pipeline of exceptionally serious resources, a considerable lot of which with first-in-class or top tier possibilities (Table 1). Until now, Ascentage Pharma has gotten 33 clinical preliminary endorsements or clearances, with more than 40 clinical examinations on-circumventing the world.

As a main biopharmaceutical organization zeroing in on the improvement of apoptosis-focusing on treatments, Ascentage Pharma has assembled a rich and strong pipeline, with five medication applicants focusing on the three key apoptotic pathways - Bcl-2, IAP, and MDM2-p53, and has progressed all these five competitors into clinical turn of events. APG-2575, the organization's orally-managed novel little atom Bcl-2 inhibitor, pulled in a lot of interest from the business and examination local area, as it is one of only a handful few Bcl-2 particular inhibitors, after venetoclax, that have entered clinical turn of events. It is additionally the principal China-created Bcl-2 inhibitor entering clinical turn of events.

In December 2020, Ascentage Pharma delivered refreshed outcomes from the clinical investigations of APG-2575 in the therapy of backslid/obstinate ongoing lymphocytic lymphoma (r/r CLL) which have selected more than 30 patients. Starter results show that an exceptionally reassuring target reaction rate (ORR) of 70% has been reached in evaluable patients. At this meeting, Dr. Yang shared extra subtleties on these outcomes.

Spotlight

According to UPI, a new study found that a vegan diet can help reduce blood sugar and body weight. Men who ate vegan meals saw a boost in their gastrointestinal hormones, which help manage weight. The beneficial gut hormones also enhance insulin secretion, regulate blood sugar, and keep us feeling full longer. The study's lead author said this research "has important implications for those with type 2 diabetes or weight problems." According to the National Institutes of Health, approximately 30 million people in the U.S. have diabetes.

Spotlight

According to UPI, a new study found that a vegan diet can help reduce blood sugar and body weight. Men who ate vegan meals saw a boost in their gastrointestinal hormones, which help manage weight. The beneficial gut hormones also enhance insulin secretion, regulate blood sugar, and keep us feeling full longer. The study's lead author said this research "has important implications for those with type 2 diabetes or weight problems." According to the National Institutes of Health, approximately 30 million people in the U.S. have diabetes.

Related News

RESEARCH

Two Labs, an Envision Pharma Group Company Acquires Riparian

Two Labs | July 08, 2021

Two Labs, an industry-leading pharma services company and a subsidiary of Envision Pharma Group, announced today the acquisition of Riparian, a pharma consulting and SaaS company that assists manufacturers with pricing regulations, reporting, strategies, and program operations. The acquisition expands Two Labs' pharma service offerings, allowing the company to offer greater insights into the financials associated with drug launch and management, better positioning manufacturers for long-term success. In addition, Riparian's in-depth knowledge of government pricing regulations and program operations, combined with their consulting, business process outsourcing, and software capabilities, enables clients to understand the financials of their drug better, ensuring that the prices reported to the government are in accordance with the current government statutes and regulations. Riparian and Two Labs will collaborate to accelerate parent company Envision Pharma Group's plans for expansion in the growing biotech pharma sector in the United States. In November 2020, Envision acquired Two Labs. Riparian will continue to operate from its current headquarters in Henderson, Nevada, with offices in Pasadena, California, and Johnson City, Tennessee. In addition, David Chan and Cynthia Hwang, co-founders, will continue with the company. About Two Labs Two Labs is a leading pharmaceutical services company that offers pharmaceutical manufacturers a range of market access, market intelligence, and commercialization services. Two Labs has managed over 200 new product launches and over 290 in-market projects from pre-launch through loss of exclusivity since its start in 2003. About Envision Pharma Group Envision Pharma Group, founded in 2001, is a global, innovative technology and scientific communications company that serves pharmaceutical, biotechnology, and medical device companies. Envision is a leading provider of evidence-based communication services and industry-leading technology solutions (iEnvision) with applications in various areas of medical affairs and related functional responsibility. Envision Pharma Group serves over 90 companies, including all top 20 pharmaceutical companies, with services and technology solutions. About Riparian Riparian is a pharma Consulting, Outsourcing, and SaaS company based in Henderson, Nevada, assisting manufacturers in navigating government pricing regulations, reporting, strategies, and program operations. Riparian is a rapidly growing, innovative company supported by a team of industry experts.

Read More

PHARMACY MARKET

Sanofi's hopes for rare blood disease candidate sutimlimab on hold after FDA blasts 3rd-party manufacturer

Sanofi | November 17, 2020

When a new drug goes in front of the FDA for consideration, a lot of moving pieces must be in place for a successful review—manufacturing standards included. That didn't happen for Sanofi, which is pressing pause on a rare disease candidate after the FDA found issues at a contract manufacturer's plant. The FDA blasted a third-party manufacturer of Sanofi's rare blood disease drug sutimlimab in a complete response letter, citing "certain deficiencies" at the contractor's site, the French drugmaker said Friday. A Sanofi spokeswoman declined to specify who the manufacturer cited in the FDA's letter was or what the nature of the deficiencies were. With its application on hold, Sanofi said it would work with its manufacturer and the FDA to resolve the issues in a "timely manner." The drugmaker didn't say how quickly it expected to turn around a new application. The untimely feedback from the FDA dims C1 inhibitor sutimlimab's chances in cold agglutinin disease (CAD), a rare blood disease characterized by anemia, fatigue and other symptoms.

Read More

RESEARCH

Pfizer, Moderna urge calm as they launch tests of vaccines against mutated COVID-19

Pfizer | December 29, 2020

After a changed, quick spreading variation of COVID-19 in the U.K. disturbed worldwide travel throughout the end of the week, an upsetting inquiry arose: Will the new antibodies from Pfizer and Moderna neutralize this startling new strain of the infection? Presently the two organizations, alongside Pfizer's COVID-19 accomplice BioNTech, are racing to quiet an apprehensive public. They're dispatching new investigations intended to demonstrate their mRNA-based shots will fight off the new Covid strain, while at the same time communicating certainty this new antibody innovation is ideal for ensuring against quickly changing infections. Pfizer and BioNTech have tried their antibody "for its capacity to kill various freak strains. Until now, we have discovered steady inclusion of the multitude of strains tried," they said in an assertion. The organizations are currently gathering information from individuals who have gotten the shot to decide how well they "might have the option to kill the new strain from the U.K.," Pfizer added. Moderna didn't promptly react to a solicitation for input yet said in an assertion gave to other news sources that it expects "that the Moderna immunization instigated insusceptibility would be defensive against the variations as of late portrayed in the U.K.," and that it "will play out extra tests in the coming a long time to affirm this desire." Pfizer brought up that when SARS-CoV-2, the infection that causes COVID-19, first arose a year prior, it was clear there was more than one strain of it, and that it was transforming as it spread. SARS-CoV-2 is a RNA infection, and all things considered, it has "astoundingly high [mutation] rates" on the grounds that the chemicals it utilizes for replication are "inclined to mistakes when making new infection duplicates," the organization said. "One reason Pfizer and BioNTech decided to use a mRNA stage is a direct result of the potential for the adaptability of the innovation in contrast with customary immunization advancements," including the capacity to change the RNA arrangement in the antibody, should a strain arise that is not covered by the current shot," Pfizer added.

Read More